Friday, June 09, 2023
Techdow USA Inc., a leading vertically integrated generic injectables company, has announced the launch of their Preservative-Free Generic Enoxaparin Sodium Prefilled Syringes. These syringes come in strengths of 30mg, 40mg, 60mg, 80mg, 100mg, 120mg, and 150mg, serving as a therapeutic equivalent to the reference listed drug (RLD) Lovenox® (Preservative Free) from Sanofi-Aventis US LLC. Techdow USA received final approval from the U.S. Food and Drug Administration for their Abbreviated New Drug Application for this product.
Enoxaparin is a low molecular weight heparin (LMWH) that acts as an anticoagulant, preventing thrombosis or the formation of blood clots. The manufacturing of Enoxaparin requires sophisticated analytical methods to ensure accurate and well-controlled processes due to its complex blend of low molecular weight substances derived from heparin.
Techdow USA, a subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., has been producing Enoxaparin Sodium Injection, USP for their global subsidiaries and partners since 2010.
According to IQVIA Health, Enoxaparin Sodium (Preservative Free) Prefilled Syringes achieved sales of approximately $530 million in both brand and generic forms over a 12-month period ending in March 2023.
Techdow USA's Enoxaparin Sodium (Preservative Free) Prefilled Syringes are supplied in single-dose 10-packs for subcutaneous use. They offer a direct ship model for ordering, aiming to enhance customer convenience.
As a prominent player in the U.S. generic pharmaceutical industry, Techdow USA focuses on the sale of generic injectable pharmaceuticals. The company is committed to expanding its product portfolio and pipeline to meet the needs of patients and customers effectively.
